Milone et al report a case of graft failure occurring after a T-cell replete allogeneic HSC transplantation that was successfully treated using an infusion of immunoselected HSC without any prior ...
MIAMI--(BUSINESS WIRE)--OrganaBio, LLC (“OrganaBio”) announces the launch of the HematoPAC™-HSC-CB CD34+ hematopoietic stem cell (HSC) product, designed to support development of HSC-based allogeneic ...
ANNVILLE, Pa.--(BUSINESS WIRE)--L2P Research, LLC and Transcell Oncologics, LLC have entered into a partnership with the purpose of marketing and the distribution of Transcell Oncologics, LLC Trans ...
TEL AVIV, Israel and WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology ...
TEL AVIV, Israel, Feb. 16, 2024 /PRNewswire/ -- BioLineRx Ltd. (BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that ...
A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the expense of the most primitive pluripotent HSCs.
TEL AVIV, Israel, May 6, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, ...
GENESIS (NCT 03246529) is a 2-part, Phase-3, randomized, double-blind, placebo-controlled, multicenter study evaluating the safety and efficacy of APHEXDA (motixafortide) plus filgrastim (G-CSF), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results